TEKMIRA PHARM
TEKMIRA PHARM operates in Diversified Metals & Mining.
TEKMIRA PHARM (I9DN) - Net Assets
Latest net assets as of September 2024: €106.89 Million EUR
Based on the latest financial reports, TEKMIRA PHARM (I9DN) has net assets worth €106.89 Million EUR as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€140.44 Million) and total liabilities (€33.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €106.89 Million |
| % of Total Assets | 76.11% |
| Annual Growth Rate | -8.87% |
| 5-Year Change | 45.74% |
| 10-Year Change | N/A |
| Growth Volatility | 39.86 |
TEKMIRA PHARM - Net Assets Trend (2016–2023)
This chart illustrates how TEKMIRA PHARM's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TEKMIRA PHARM (2016–2023)
The table below shows the annual net assets of TEKMIRA PHARM from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €106.02 Million | -22.53% |
| 2022-12-31 | €136.85 Million | -19.23% |
| 2021-12-31 | €169.44 Million | +66.17% |
| 2020-12-31 | €101.97 Million | +40.17% |
| 2019-12-31 | €72.74 Million | -63.67% |
| 2018-12-31 | €200.23 Million | +9.73% |
| 2017-12-31 | €182.47 Million | -10.11% |
| 2016-12-31 | €203.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to TEKMIRA PHARM's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 62550300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.38 Billion | 1304.18% |
| Total Equity | €106.02 Million | 100.00% |
TEKMIRA PHARM Competitors by Market Cap
The table below lists competitors of TEKMIRA PHARM ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hemlo Mining Corp.
V:HMMC
|
$38.61K |
|
A-Labs Capital II Corp
V:ALAB-P
|
$38.61K |
|
WEATHERF INT REG.
F:WH4
|
$38.62K |
|
VIVA3F
SA:VIVA3F
|
$38.64K |
|
Assetco Plc
LSE:ASTO
|
$38.49K |
|
OMNIA HOLD
BE:OHZ
|
$38.49K |
|
Metals Exploration Plc
LSE:MTL
|
$38.48K |
|
American Commerce Solutions Inc
PINK:AACS
|
$38.47K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TEKMIRA PHARM's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 136,852,000 to 106,018,000, a change of -30,834,000 (-22.5%).
- Net loss of 72,849,000 reduced equity.
- New share issuances of 29,852,000 increased equity.
- Other factors increased equity by 12,163,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-72.85 Million | -68.71% |
| Share Issuances | €29.85 Million | +28.16% |
| Other Changes | €12.16 Million | +11.47% |
| Total Change | €- | -22.53% |
Book Value vs Market Value Analysis
This analysis compares TEKMIRA PHARM's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.18x to 6.28x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €3.31 | €3.92 | x |
| 2018-12-31 | €3.53 | €3.92 | x |
| 2019-12-31 | €1.12 | €3.92 | x |
| 2020-12-31 | €1.12 | €3.92 | x |
| 2021-12-31 | €1.17 | €3.92 | x |
| 2022-12-31 | €0.87 | €3.92 | x |
| 2023-12-31 | €0.62 | €3.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TEKMIRA PHARM utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -68.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -401.57%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.36x
- Recent ROE (-68.71%) is above the historical average (-87.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -189.24% | -25765.53% | 0.01x | 1.36x | €-404.46 Million |
| 2017 | -46.26% | -788.91% | 0.05x | 1.30x | €-102.66 Million |
| 2018 | -28.50% | -959.80% | 0.03x | 1.14x | €-77.08 Million |
| 2019 | -211.32% | -2557.36% | 0.06x | 1.45x | €-161.00 Million |
| 2020 | -62.52% | -921.97% | 0.05x | 1.34x | €-73.94 Million |
| 2021 | -45.00% | -693.91% | 0.05x | 1.21x | €-93.19 Million |
| 2022 | -50.75% | -178.01% | 0.20x | 1.43x | €-83.14 Million |
| 2023 | -68.71% | -401.57% | 0.13x | 1.36x | €-83.45 Million |
Industry Comparison
This section compares TEKMIRA PHARM's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $114,212,818,724
- Average return on equity (ROE) among peers: -9.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TEKMIRA PHARM (I9DN) | €106.89 Million | -189.24% | 0.31x | $38.60K |
| HORIBA (01H) | $204.49 Billion | 10.42% | 0.82x | $989.01K |
| Tokyu Corporation (01T) | $779.37 Billion | 3.34% | 2.35x | $99.73K |
| GUANGZHOU AUTO -H- (02G) | $122.28 Billion | 6.59% | 0.55x | $4.05K |
| MOSAIC (02M) | $10.60 Billion | 4.43% | 0.90x | $280.83K |
| MOSAIC (02M.SG) (02M) | $9.56 Billion | 10.46% | 0.82x | $247.21K |
| CHINA JO-JO DRGSTRS (04CN.SG) (04CN) | $16.67 Million | -126.83% | 4.46x | $1.55 Million |
| KRAKATAU STEEL -B- (07K) | $552.59 Million | 3.52% | 4.72x | $166.99 |
| CN MODERN DAIRY (07M) | $7.12 Billion | -10.42% | 1.50x | $1.68K |
| TOURMALINE OIL (08T) | $7.22 Billion | 4.81% | 0.41x | $381.02K |
| ASIA CASSAVA RESOUR (0ACS) | $913.15 Million | 2.86% | 1.55x | $325.03 |